152 related articles for article (PubMed ID: 9010274)
1. IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases.
Doré P; Lelièvre E; Morel F; Brizard A; Fourcin M; Clemént C; Ingrand P; Daneski L; Gascan H; Wijdenes J; Gombert J; Preud'homme JL; Lecron JC
Clin Exp Immunol; 1997 Jan; 107(1):182-8. PubMed ID: 9010274
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-6 receptor levels in pleural effusions.
Yokoyama A; Kohno N; Fujino S; Abe M; Ishida O; Hiwada K
Respir Med; 1996 Jul; 90(6):329-32. PubMed ID: 8759474
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
4. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
Müller-Newen G; Küster A; Hemmann U; Keul R; Horsten U; Martens A; Graeve L; Wijdenes J; Heinrich PC
J Immunol; 1998 Dec; 161(11):6347-55. PubMed ID: 9834125
[TBL] [Abstract][Full Text] [Related]
5. Soluble gp130 is up-regulated in the implantation window and shows altered secretion in patients with primary unexplained infertility.
Sherwin JR; Smith SK; Wilson A; Sharkey AM
J Clin Endocrinol Metab; 2002 Aug; 87(8):3953-60. PubMed ID: 12161539
[TBL] [Abstract][Full Text] [Related]
6. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
Int Immunol; 1996 Apr; 8(4):595-602. PubMed ID: 8722639
[TBL] [Abstract][Full Text] [Related]
7. Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters?
Kovacs E; Kuehn JJ
Biomed Pharmacother; 2002 May; 56(3):152-8. PubMed ID: 12046687
[TBL] [Abstract][Full Text] [Related]
8. Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130.
Yasukawa K; Futatsugi K; Saito T; Yawata H; Narazaki M; Suzuki H; Taga T; Kishimoto T
Immunol Lett; 1992 Feb; 31(2):123-30. PubMed ID: 1740350
[TBL] [Abstract][Full Text] [Related]
9. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
10. Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human CD34+ cells.
Tajima S; Tsuji K; Ebihara Y; Sui X; Tanaka R; Muraoka K; Yoshida M; Yamada K; Yasukawa K; Taga T; Kishimoto T; Nakahata T
J Exp Med; 1996 Oct; 184(4):1357-64. PubMed ID: 8879208
[TBL] [Abstract][Full Text] [Related]
11. [Determination of serum soluble interleukin-6 receptor and soluble gp130 levels in patient with pregnancy induced hypertension and its significance].
Li Y; Wang Y; Qi L
Zhonghua Fu Chan Ke Za Zhi; 2001 Jan; 36(1):18-9. PubMed ID: 11778537
[TBL] [Abstract][Full Text] [Related]
12. Proinflammatory cytokine levels in patients with lung cancer and carcinomatous pleurisy.
Hoheisel G; Izbicki G; Roth M; Chan CH; Reichenberger F; Schauer J; Perruchoud AP
Respiration; 1998; 65(3):183-6. PubMed ID: 9670298
[TBL] [Abstract][Full Text] [Related]
13. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
[TBL] [Abstract][Full Text] [Related]
14. Compartmentalization of pro-inflammatory cytokines in tuberculous pleurisy.
Hoheisel G; Izbicki G; Roth M; Chan CH; Leung JC; Reichenberger F; Schauer J; Perruchoud AP
Respir Med; 1998 Jan; 92(1):14-7. PubMed ID: 9519218
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
16. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
Aparicio-Siegmund S; Garbers Y; Flynn CM; Waetzig GH; Gouni-Berthold I; Krone W; Berthold HK; Laudes M; Rose-John S; Garbers C
Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E411-E420. PubMed ID: 31237452
[TBL] [Abstract][Full Text] [Related]
17. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients.
Kovacs E
Biomed Pharmacother; 2001 Sep; 55(7):391-6. PubMed ID: 11669502
[TBL] [Abstract][Full Text] [Related]
18. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.
Narazaki M; Yasukawa K; Saito T; Ohsugi Y; Fukui H; Koishihara Y; Yancopoulos GD; Taga T; Kishimoto T
Blood; 1993 Aug; 82(4):1120-6. PubMed ID: 8353278
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.
Nikolaus S; Waetzig GH; Butzin S; Ziolkiewicz M; Al-Massad N; Thieme F; Lövgren U; Rasmussen BB; Reinheimer TM; Seegert D; Rosenstiel P; Szymczak S; Schreiber S
Int J Colorectal Dis; 2018 Jul; 33(7):927-936. PubMed ID: 29748708
[TBL] [Abstract][Full Text] [Related]
20. Circulating interleukin 6 and soluble forms of its receptors in relation to resting energy expenditure in women with anorexia nervosa.
Karczewska-Kupczewska M; Adamska A; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
Clin Endocrinol (Oxf); 2013 Dec; 79(6):812-6. PubMed ID: 23199226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
